A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial - Berger, Anne Katrin; Abel, Ulrich; Kloor, Matthias; Ose, Jennifer; Weber, Tim; Stange, Annika; Haag, Georg Martin; Haberkorn, Uwe; Jäger, Dirk (BMC cancer, 2012)
Gesehen am 29.10.2024